PURPLE BIOTECH LTD-ADR (PPBT)
US74638P1093 - ADR
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT,...
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity...
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
PPBT stock results show that Purple Biotech met analyst estimates for earnings per share the fourth quarter of 2023.
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Purple Biotech (NASDAQ:PPBT) just reported results for the fourth quarter of 20...
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control...
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech...
Purple Biotech stock climbs 9% on Phase 2 study update (NASDAQ:PPBT)
Shares of Purple Biotech (PPBT) climbed 9% in morning trading Thursday after the company said it has determined the recommended dose of its oncology drug candid
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien...
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
Purple Biotech Reports Third Quarter 2023 Financial Results
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24...
Purple Biotech Fortifies NT219 Patent Protection
Purple Biotech files to sell 4.65M ADS for holders (NASDAQ:PPBT)
Purple Biotech (PPBT) filed a prospectus related to the resale by the selling shareholders of up to 4.65M American Depositary Shares. This prospectus is not an
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company...
Purple Biotech Announces $5 Million Registered Direct Offering
Purple Biotech Announces $5 Million Registered Direct Offering
REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company...
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort...
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
Purple Biotech Reports Second Quarter 2023 Financial Results
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies...